赛伦生物12月23日获融资买入159.02万元，融资余额1.58亿元

Core Viewpoint - Sirun Biotech's stock experienced a slight decline of 0.90% on December 23, with a trading volume of 9.94 million yuan, indicating a stable market presence despite minor fluctuations [1]. Financing Summary - On December 23, Sirun Biotech had a financing buy-in amount of 1.59 million yuan, with a net financing buy of 730,600 yuan after repaying 859,600 yuan [1]. - The total financing and securities balance for Sirun Biotech reached 158 million yuan, accounting for 6.66% of its market capitalization, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, there were no shares sold or repaid on December 23, with the securities lending balance also at zero, placing it in the 90th percentile of the past year, suggesting a lack of short-selling activity [1]. Company Performance Summary - As of September 30, Sirun Biotech had 6,635 shareholders, a decrease of 14.10% from the previous period, while the average number of circulating shares per person increased by 183.92% to 16,310 shares [2]. - For the period from January to September 2025, Sirun Biotech reported a revenue of 175 million yuan, reflecting a year-on-year growth of 1.07%, and a net profit attributable to shareholders of 64.21 million yuan, which is a 2.01% increase year-on-year [2]. - Since its A-share listing, Sirun Biotech has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2].